402 related articles for article (PubMed ID: 26422112)
1. The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.
Jones K; Wockner L; Brennan RM; Keane C; Chattopadhyay PK; Roederer M; Price DA; Cole DK; Hassan B; Beck K; Gottlieb D; Ritchie DS; Seymour JF; Vari F; Crooks P; Burrows SR; Gandhi MK
Clin Exp Immunol; 2016 Feb; 183(2):206-20. PubMed ID: 26422112
[TBL] [Abstract][Full Text] [Related]
2. HLA class I associations with EBV+ post-transplant lymphoproliferative disorder.
Jones K; Wockner L; Thornton A; Gottlieb D; Ritchie DS; Seymour JF; Kumarasinghe G; Gandhi MK
Transpl Immunol; 2015 Mar; 32(2):126-30. PubMed ID: 25731678
[TBL] [Abstract][Full Text] [Related]
3. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
5. Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups.
Huang X; Kushekhar K; Nolte I; Kooistra W; Visser L; Bouwman I; Kouprie N; Veenstra R; van Imhoff G; Olver B; Houlston RS; Poppema S; Diepstra A; Hepkema B; van den Berg A
Blood; 2011 Nov; 118(19):5211-7. PubMed ID: 21921049
[TBL] [Abstract][Full Text] [Related]
6. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.
Murray PG; Constandinou CM; Crocker J; Young LS; Ambinder RF
Blood; 1998 Oct; 92(7):2477-83. PubMed ID: 9746788
[TBL] [Abstract][Full Text] [Related]
7. Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells.
Pavlovic A; Glavina Durdov M; Capkun V; Jakelic Pitesa J; Bozic Sakic M
Med Sci Monit; 2016 Jul; 22():2340-6. PubMed ID: 27377121
[TBL] [Abstract][Full Text] [Related]
8. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
9. Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.
Bryden H; MacKenzie J; Andrew L; Alexander FE; Angus B; Krajewski AS; Armstrong AA; Gray D; Cartwright RA; Kane E; Wright DH; Taylor P; Jarrett RF
Int J Cancer; 1997 Aug; 72(4):614-8. PubMed ID: 9259400
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
11. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
Li C; Romero-Masters JC; Huebner S; Ohashi M; Hayes M; Bristol JA; Nelson SE; Eichelberg MR; Van Sciver N; Ranheim EA; Scott RS; Johannsen EC; Kenney SC
PLoS Pathog; 2020 Jun; 16(6):e1008590. PubMed ID: 32542010
[TBL] [Abstract][Full Text] [Related]
12. HLA-A*02:07 is a protective allele for EBV negative and a susceptibility allele for EBV positive classical Hodgkin lymphoma in China.
Huang X; Hepkema B; Nolte I; Kushekhar K; Jongsma T; Veenstra R; Poppema S; Gao Z; Visser L; Diepstra A; van den Berg A
PLoS One; 2012; 7(2):e31865. PubMed ID: 22355400
[TBL] [Abstract][Full Text] [Related]
13. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
Taylor GS; Haigh TA; Gudgeon NH; Phelps RJ; Lee SP; Steven NM; Rickinson AB
J Virol; 2004 Jan; 78(2):768-78. PubMed ID: 14694109
[TBL] [Abstract][Full Text] [Related]
14. Contribution of HLA class I allele expression to CD8+ T-cell responses against Epstein-Barr virus.
Höllsberg P
Scand J Immunol; 2002 Feb; 55(2):189-95. PubMed ID: 11896935
[TBL] [Abstract][Full Text] [Related]
15. Computational prediction and identification of Epstein-Barr virus latent membrane protein 2A antigen-specific CD8+ T-cell epitopes.
Wang B; Yao K; Liu G; Xie F; Zhou F; Chen Y
Cell Mol Immunol; 2009 Apr; 6(2):97-103. PubMed ID: 19403058
[TBL] [Abstract][Full Text] [Related]
16. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
[TBL] [Abstract][Full Text] [Related]
17. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
Rancan C; Schirrmann L; Hüls C; Zeidler R; Moosmann A
PLoS Pathog; 2015 Jun; 11(6):e1004906. PubMed ID: 26067064
[TBL] [Abstract][Full Text] [Related]
18. Severity of Acute Infectious Mononucleosis Correlates with Cross-Reactive Influenza CD8 T-Cell Receptor Repertoires.
Aslan N; Watkin LB; Gil A; Mishra R; Clark FG; Welsh RM; Ghersi D; Luzuriaga K; Selin LK
mBio; 2017 Dec; 8(6):. PubMed ID: 29208744
[TBL] [Abstract][Full Text] [Related]
19. Identification and prevalence of CD8(+) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2.
Meij P; Leen A; Rickinson AB; Verkoeijen S; Vervoort MB; Bloemena E; Middeldorp JM
Int J Cancer; 2002 May; 99(1):93-9. PubMed ID: 11948498
[TBL] [Abstract][Full Text] [Related]
20. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
Zhang B; Zong Y; He J; Zhong B; Lin S
Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
